Immunotherapy in hematologic malignancies: past, present, and future

The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid malignancies. Prior to its designation as the Science B...

Descripción completa

Detalles Bibliográficos
Autores principales: Im, Annie, Pavletic, Steven Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402171/
https://www.ncbi.nlm.nih.gov/pubmed/28434396
http://dx.doi.org/10.1186/s13045-017-0453-8
_version_ 1783231174468960256
author Im, Annie
Pavletic, Steven Z.
author_facet Im, Annie
Pavletic, Steven Z.
author_sort Im, Annie
collection PubMed
description The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid malignancies. Prior to its designation as the Science Breakthrough of the Year in 2013, cancer immunotherapy was active in the treatment of hematologic malignancies. This review provides a broad overview of the past, present, and potential future of immunotherapy in hematologic malignancies.
format Online
Article
Text
id pubmed-5402171
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54021712017-04-24 Immunotherapy in hematologic malignancies: past, present, and future Im, Annie Pavletic, Steven Z. J Hematol Oncol Review The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid malignancies. Prior to its designation as the Science Breakthrough of the Year in 2013, cancer immunotherapy was active in the treatment of hematologic malignancies. This review provides a broad overview of the past, present, and potential future of immunotherapy in hematologic malignancies. BioMed Central 2017-04-24 /pmc/articles/PMC5402171/ /pubmed/28434396 http://dx.doi.org/10.1186/s13045-017-0453-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Im, Annie
Pavletic, Steven Z.
Immunotherapy in hematologic malignancies: past, present, and future
title Immunotherapy in hematologic malignancies: past, present, and future
title_full Immunotherapy in hematologic malignancies: past, present, and future
title_fullStr Immunotherapy in hematologic malignancies: past, present, and future
title_full_unstemmed Immunotherapy in hematologic malignancies: past, present, and future
title_short Immunotherapy in hematologic malignancies: past, present, and future
title_sort immunotherapy in hematologic malignancies: past, present, and future
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402171/
https://www.ncbi.nlm.nih.gov/pubmed/28434396
http://dx.doi.org/10.1186/s13045-017-0453-8
work_keys_str_mv AT imannie immunotherapyinhematologicmalignanciespastpresentandfuture
AT pavleticstevenz immunotherapyinhematologicmalignanciespastpresentandfuture

Ejemplares similares